Top

Cancer Imaging

Published in:

Open Access 01-12-2024 | Breast Cancer | Review

Predictive value of background parenchymal enhancement on breast magnetic resonance imaging for pathological tumor response to neoadjuvant chemotherapy in breast cancers: a systematic review

Authors: Xue Li, Fuhua Yan

Published in: Cancer Imaging | Issue 1/2024

Abstract

Objectives

This review aimed to assess the predictive value of background parenchymal enhancement (BPE) on breast magnetic resonance imaging (MRI) as an imaging biomarker for pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT).

Methods

Two reviewers independently performed a systemic literature search using the PubMed, MEDLINE, and Embase databases for studies published up to 11 June 2022. Data from relevant articles were extracted to assess the relationship between BPE and pCR.

Results

This systematic review included 13 studies with extensive heterogeneity in population characteristics, MRI follow-up points, MRI protocol, NACT protocol, pCR definition, and BPE assessment. Baseline BPE levels were not associated with pCR, except in 1 study that reported higher baseline BPE of the younger participants (< 55 years) in the pCR group than the non-pCR group. A total of 5 studies qualitatively assessed BPE levels and indicated a correlation between reduced BPE after NACT and pCR; however, among the studies that quantitatively measured BPE, the same association was observed only in the subgroup analysis of 2 articles that assessed the status of hormone receptor and human epidermal growth factor receptor 2. In addition, the predictive ability of early BPE changes for pCR was reported in several articles and remains controversial.

Conclusions

Changes in BPE may be a promising imaging biomarker for predicting pCR in breast cancer. Because current studies remain insufficient, particularly those that quantitatively measure BPE, prospective and multicenter large-sample studies are needed to confirm this relationship.

Available only for authorised users

Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15(7):2483–93.CrossRefPubMed

Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2005;23(12):2694–702.CrossRefPubMed

Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778–85. https://doi.org/10.1200/JCO.2007.15.0235.CrossRefPubMed

Vaidya JS, Massarut S, Vaidya HJ, et al. Rethinking neoadjuvant chemotherapy for breast cancer. BMJ. 2018;360:j5913. https://doi.org/10.1136/bmj.j5913.CrossRefPubMed

Schott AF, Hayes DF. Defining the benefits of neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2012;30(15):1747–9. https://doi.org/10.1200/JCO.2011.41.3161.CrossRefPubMed

Derks MGM, van de Velde CJH. Neoadjuvant chemotherapy in breast cancer: more than just downsizing. Lancet Oncol. 2018;19(1):2–3. https://doi.org/10.1016/S1470-2045(17)30914-2.CrossRefPubMed

Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275–81. https://doi.org/10.1200/JCO.2007.14.4147.CrossRefPubMed

Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72. https://doi.org/10.1016/S0140-6736(13)62422-8.CrossRefPubMed

Liao GJ, Henze Bancroft LC, Strigel RM, et al. Background parenchymal enhancement on breast MRI: A comprehensive review. J Magn Reson Imaging. 2020;51(1):43–61. https://doi.org/10.1002/jmri.26762.CrossRefPubMed

10.

Joshi S, Garlapati C, Bhattarai S, et al. Exosomal Metabolic Signatures Are Associated with Differential Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer. Int J Mol Sci. 2022;23(10). https://doi.org/10.3390/ijms23105324.

11.

Sippo DA, Warden GI, Andriole KP, et al. Automated extraction of BI-RADS final assessment categories from radiology reports with natural language processing. J Digit Imaging. 2013;26(5):989–94. https://doi.org/10.1007/s10278-013-9616-5.CrossRefPubMedPubMedCentral

12.

Kim JY, Kim SH, Kim YJ, et al. Enhancement parameters on dynamic contrast enhanced breast MRI: do they correlate with prognostic factors and subtypes of breast cancers? Magn Reson Imaging. 2015;33(1):72–80. https://doi.org/10.1016/j.mri.2014.08.034.CrossRefPubMed

13.

Thompson CM, Mallawaarachchi I, Dwivedi DK, et al. The Association of Background Parenchymal Enhancement at Breast MRI with Breast Cancer: a systematic review and meta-analysis. Radiology. 2019;292(3):552–61. https://doi.org/10.1148/radiol.2019182441.CrossRefPubMed

14.

You C, Peng W, Zhi W, et al. Association between background parenchymal enhancement and pathologic complete remission throughout the neoadjuvant chemotherapy in breast cancer patients. Transl Oncol. 2017;10(5):786–92. https://doi.org/10.1016/j.tranon.2017.07.005.CrossRefPubMedPubMedCentral

15.

Rella R, Bufi E, Belli P, et al. Association between background parenchymal enhancement and tumor response in patients with breast cancer receiving neoadjuvant chemotherapy. Diagn Interv Imaging. 2020;101(10):649–55. https://doi.org/10.1016/j.diii.2020.05.010.CrossRefPubMed

16.

Preibsch H, Wanner L, Bahrs SD, et al. Background parenchymal enhancement in breast MRI before and after neoadjuvant chemotherapy: correlation with tumour response. Eur Radiol. 2016;26(6):1590–6. https://doi.org/10.1007/s00330-015-4011-x.CrossRefPubMed

17.

Chen JH, Yu HJ, Hsu C, Mehta RS, Carpenter PM, Su MY. Background Parenchymal Enhancement of the Contralateral Normal Breast: Association with Tumor Response in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. Transl Oncol. 2015;8(3):204–9. https://doi.org/10.1016/j.tranon.2015.04.001.CrossRefPubMedPubMedCentral

18.

Teixeira SRC, Camargo HSAD, Ramalho S, et al. Breast cancer and magnetic resonance imaging (MRI): Background parenchymal enhancement (BPE) predicting response to neoadjuvant chemotherapy. Cancer Research. 2018;78(4). https://doi.org/10.1158/15387445.SABCS17-P4-02-09.

19.

Onishi N, Li W, Newitt DC, et al. Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response. Radiology. 2021;301(2):295–308. https://doi.org/10.1148/radiol.2021203645.CrossRefPubMed

20.

Dong JM, Wang HX, Zhong XF, et al. Changes in background parenchymal enhancement in HER2-positive breast cancer before and after neoadjuvant chemotherapy: association with pathologic complete response. Medicine (Baltimore). 2018;97(43):e12965. https://doi.org/10.1097/md.0000000000012965.CrossRefPubMed

21.

You C, Gu Y, Peng W, et al. Decreased background parenchymal enhancement of the contralateral breast after two cycles of neoadjuvant chemotherapy is associated with tumor response in HER2-positive breast cancer. Acta Radiol. 2018;59(7):806–12. https://doi.org/10.1177/0284185117738560.CrossRefPubMed

22.

Choi BB, Kim SH. Effective factors to raise diagnostic performance of breast MRI for diagnosing pathologic complete response in breast cancer patients after neoadjuvant chemotherapy. Acta Radiol. 2015;56(7):790–7. https://doi.org/10.1177/0284185114538622.CrossRefPubMed

23.

Arasu VA, Kim P, Li W, et al. Predictive Value of Breast MRI Background Parenchymal Enhancement for Neoadjuvant Treatment Response among HER2- Patients. J Breast Imaging. 2020;2(4):352–60. https://doi.org/10.1093/jbi/wbaa028.CrossRefPubMedPubMedCentral

24.

Oh SJ, Chae EY, Cha JH, Shin HJ, Choi WJ, Kim HH. Relationship between background parenchymal enhancement on breast MRI and pathological tumor response in breast cancer patients receiving neoadjuvant chemotherapy. Br J Radiol. 2018;91(1088):20170550. https://doi.org/10.1259/bjr.20170550.CrossRefPubMedPubMedCentral

25.

Forgia DL, Vestito A, Lasciarrea M, et al. Response predictivity to neoadjuvant therapies in breast cancer: A qualitative analysis of background parenchymal enhancement in dce-mri. Journal of Personalized Medicine. 2021;11(4). https://doi.org/10.3390/jpm11040256.

26.

Moliere S, Oddou I, Noblet V, Veillon F, Mathelin C. Quantitative background parenchymal enhancement to predict recurrence after neoadjuvant chemotherapy for breast cancer. Sci Rep. 2019;9(1):19185. https://doi.org/10.1038/s41598-019-55820-5.ADSCrossRefPubMedPubMedCentral

27.

Whiting PF, Rutjes AWS, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529–36. https://doi.org/10.7326/0003-4819-155-8-201110180-00009.CrossRefPubMed

28.

Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026.CrossRefPubMed

29.

Niukkanen A, Okuma H, Sudah M, et al. Quantitative Three-Dimensional Assessment of the Pharmacokinetic Parameters of Intra- and Peri-tumoural Tissues on Breast Dynamic Contrast-Enhanced Magnetic Resonance Imaging. J Digit Imaging. 2021;34(5):1110–9. https://doi.org/10.1007/s10278-021-00509-3.CrossRefPubMedPubMedCentral

30.

Colleoni M, Viale G, Zahrieh D, et al. Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. Ann Oncol. 2008;19(3):465–72.CrossRefPubMed

31.

Schrading S, Kuhl CK. Breast Cancer: Influence of Taxanes on Response Assessment with Dynamic Contrast-enhanced MR Imaging. Radiology. 2015;277(3):687–96. https://doi.org/10.1148/radiol.2015150006.CrossRefPubMed

32.

King V, Kaplan J, Pike MC, et al. Impact of tamoxifen on amount of fibroglandular tissue, background parenchymal enhancement, and cysts on breast magnetic resonance imaging. Breast J. 2012;18(6):527–34. https://doi.org/10.1111/tbj.12002.CrossRefPubMed

33.

Chen J-H, Yu H, Lin M, Mehta RS, Su M-Y. Background parenchymal enhancement in the contralateral normal breast of patients undergoing neoadjuvant chemotherapy measured by DCE-MRI. Magn Reson Imaging. 2013;31(9):1465–71. https://doi.org/10.1016/j.mri.2013.07.014.CrossRefPubMedPubMedCentral

Title: Predictive value of background parenchymal enhancement on breast magnetic resonance imaging for pathological tumor response to neoadjuvant chemotherapy in breast cancers: a systematic review
Authors: Xue Li
Fuhua Yan
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Magnetic Resonance Imaging
Magnetic Resonance Imaging
Cytostatic Therapy
Published in: Cancer Imaging / Issue 1/2024
Electronic ISSN: 1470-7330
DOI: https://doi.org/10.1186/s40644-024-00672-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

HCC portal hypertension imaging score derived from CT predicts re-bleeding and mortality after acute variceal bleeding

A clinical-radiomics nomogram based on dual-layer spectral detector CT to predict cancer stage in pancreatic ductal adenocarcinoma

Radiomics signature for dynamic changes of tumor-infiltrating CD8+ T cells and macrophages in cervical cancer during chemoradiotherapy

Effect of Hashimoto’s thyroiditis on the dual-energy CT quantitative parameters and performance in diagnosing metastatic cervical lymph nodes in patients with papillary thyroid cancer

CT radiomics based on different machine learning models for classifying gross tumor volume and normal liver tissue in hepatocellular carcinoma

Radiomics signature based on robust features derived from diffusion data for differentiation between benign and malignant solitary pulmonary lesions

Keynote webinar | Spotlight on antibody–drug conjugates in cancer